On August 23, 2021, the Institute for Quality and Efficiency in Health Care (IQWiG) has presented an updated draft version (6.1) of its general methods. The interested parties can submit written comments until the deadline of October 4, 2021.
The most important changes are listed below:
- The IQWiG is implementing conduction of evidence review concerning medical guidelines within its new product "Evidence report";
- For the qualitative summary of study results, the IQWiG presents the new concept of implied effects;
- To determine the extent of the additional benefit of new drugs in the early benefit assessment, the IQWiG presents a revised approach for continuous data review.
The IQWiG's general methods document describes in detail and transparently the scientific standards according to which the Institute assesses the benefits and harms of medical measures. The paper is being updated regularly; version 6.0 was published in early November 2020.
The full details in German can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.